| 1 |
35597428 | BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. | 2022 Aug |
1 |
| 2 |
31949019 | Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. | 2021 Jan 1 |
1 |
| 3 |
33089525 | A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. | 2021 Feb |
1 |
| 4 |
33760219 | Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation. | 2021 May |
1 |
| 5 |
33775465 | Revisiting Richter transformation in the era of novel CLL agents. | 2021 Sep |
1 |
| 6 |
34174982 | Genomics of Resistance to Targeted Therapies. | 2021 Aug |
1 |
| 7 |
34214199 | MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. | 2021 Oct |
2 |
| 8 |
34771616 | Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. | 2021 Oct 29 |
1 |
| 9 |
31180577 | Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. | 2020 Jan 1 |
2 |
| 10 |
32103491 | Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. | 2020 Jun |
1 |
| 11 |
32184360 | Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. | 2020 Apr 24 |
1 |
| 12 |
32232486 | Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. | 2020 Jun 11 |
1 |
| 13 |
32673127 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. | 2020 Aug |
2 |
| 14 |
33154951 | Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. | 2020 Oct 26 |
1 |
| 15 |
30940652 | Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. | 2019 Jul 1 |
1 |
| 16 |
31243043 | Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. | 2019 Aug 15 |
2 |
| 17 |
29381098 | Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? | 2018 Mar |
3 |
| 18 |
29743179 | A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. | 2018 Aug 2 |
1 |
| 19 |
30026342 | Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. | 2018 Dec |
1 |
| 20 |
30093506 | The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. | 2018 Oct |
1 |
| 21 |
30344948 | Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder. | 2018 Sep 28 |
1 |
| 22 |
27776353 | Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. | 2017 Jan 24 |
1 |
| 23 |
28049639 | Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. | 2017 Mar 16 |
1 |
| 24 |
28348046 | B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. | 2017 Aug 1 |
1 |
| 25 |
28366935 | PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. | 2017 Jul |
2 |
| 26 |
28993409 | MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. | 2017 Dec 15 |
1 |
| 27 |
27542411 | The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. | 2016 Oct 14 |
8 |
| 28 |
25972157 | Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. | 2015 Jul 2 |
6 |
| 29 |
24659631 | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. | 2014 May 22 |
1 |
| 30 |
24869598 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. | 2014 Jun 12 |
1 |